# US 2021/0275608 A1 · Compositions and Methods for Detecting and Treating Brain Injury Associated Fatigue and Altered Cognition (BIAFAC)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275608 A1
- Document ID: US20210275608A1
- Status: Published application
- Kind: A1
- Application number: 17/192,679
- Filed: 2021-03-04
- Published: 2021-09-09
- Earliest claimed: 2018-06-21
- Applicants: Board of Regents, The University of Texas System
- Inventors: Randall J. Urban; Melinda Sheffield-Moore; Richard Pyles; Brent Masel
- Web page: https://patentgrep.com/patent/US20210275608A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/689: for bacteria
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention includes composition, methods and kits for detecting and treating brain injury associated fatigue or altered cognition (BIAFAC) in a human patient comprising: identifying a human patient in need of treatment for brain injury associated fatigue or altered cognition associated with an altered intestinal flora; and providing the human patient with a composition comprising at least one of: a Prevotella spp or a Bacteroidies spp bacteria, or one or more agents that increase the amount of the Prevotella spp or the Bacteroidies spp bacteria in an intestinal flora of the human patient to reduce or eliminate the brain injury associated fatigue or altered cognition.

## Claims

### Claim 1

A method of identifying a patient with a brain injury associated fatigue or altered cognition (BIAFAC) that will benefit from a probiotic bacteria treatment comprising:
identifying a human patient with a brain injury associated fatigue or altered cognition;
obtaining a biological sample from the patient that comprises gut intestinal flora; and
determining whether the gut intestinal flora in the biological sample comprises a decrease in the presence of probiotic bacteria selected from at least one of Prevotella spp or Bacteroidies spp bacteria, when compared to a normal human sample.

### Claim 2 (depends on 1)

The method of claim 1, further comprising treating the patient with a composition comprising one or more probiotic bacteria selected from at least one of: Prevotella spp or Bacteroidies spp, or one or more agents that increase the amount of Prevotella spp or Bacteroidies spp in an intestinal flora of the patient, wherein a composition comprises an amount effective to reduce or eliminate the brain injury associated fatigue or altered cognition.

### Claim 3 (depends on 1)

The method of claim 1, further comprising providing the patient with a fecal transplant comprising Prevotella spp or Bacteroidies spp.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biological sample is a fecal sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein a presence of a probiotic bacteria is determined by at least one of metagenomic shotgun sequencing of bacteria, quantitative PCR assays or metabolic LC-MS analysis of bacterial metabolites.

### Claim 6 (depends on 1)

The method of claim 1, further comprising the step of providing the patient with an agent that reduces or eliminates Ruminococcaceae genus bacteria.

### Claim 7 (depends on 6)

The method of claim 6, wherein the agent that reduces or eliminates Ruminococcaceae genus bacteria is selected from an amino acid mixture, an antibacterial agent, a bacteriophage, or an antimicrobial CRISP-Cas system agent.

### Claim 8 (depends on 1)

The method of claim 1, wherein the human patient has brain injury that is chronic, mild, or undiagnosed, or is caused by stroke, hemorrhage, surgery, or radiation.

### Claim 9 (depends on 1)

The method of claim 1, wherein a composition is provided to the patient that further comprises an amino acid mixture that promotes a growth of Prevotella spp or Bacteroidies spp.

### Claim 10 (depends on 1)

The method of claim 1, wherein a composition is provided to the patient further comprises an amino acid mixture that reduces or eliminates Ruminococcaceae genus bacteria.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient did not receive a concurrent antibiotic or a probiotic therapy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more bacteria is listed in Tables 3, 4, 5 and 6.

### Claim 13 (depends on 1)

The method of claim 1, further comprising providing the human patient a bacterial composition that is modified to correct a TBI flora to a normal flora is provided before, during, or after undergoing a colon cleanse treatment, delivered by colonoscope, wherein the bacterial composition is not a fecal transplant, or wherein bacteria are lab-grown, or wherein bacteria are lab-grown and customized to specifically modify a TBI flora of a specific patient.

### Claim 14

A method of treating a human patient with a brain injury associated fatigue or altered cognition (BIAFAC) that will benefit from a probiotic bacteria treatment comprising:
identifying a human patient with a brain injury associated fatigue or altered cognition;
obtaining a biological sample from the human patient that comprises gut intestinal flora; and
determining whether the gut intestinal flora in the biological sample comprises a decrease in the presence of probiotic bacteria selected from at least one of Prevotella spp or Bacteroidies spp bacteria, when compared to a normal human sample; and
providing the human patient with a composition comprising one or more probiotic bacteria selected from at least one of: Prevotella spp or Bacteroidies spp, in an effective amount sufficient to reduce or eliminate the brain injury associated fatigue or altered cognition.

### Claim 15 (depends on 14)

The method of claim 14, wherein the composition comprises one or more probiotic bacteria selected from at least one of: Prevotella spp or Bacteroidies spp, or one or more agents that increase the amount of Prevotella spp or Bacteroidies spp in an intestinal flora of the patient, wherein a composition comprises an amount effective to reduce or eliminate the brain injury associated fatigue or altered cognition.

### Claim 16 (depends on 14)

The method of claim 14, wherein the composition comprises a fecal transplant comprising Prevotella spp or Bacteroidies spp.

### Claim 17 (depends on 14)

The method of claim 14, wherein a presence of a probiotic bacteria is determined by at least one of metagenomic shotgun sequencing of bacteria, quantitative PCR assays or metabolic LC-MS analysis of bacterial metabolites.

### Claim 18 (depends on 14)

The method of claim 14, further comprising the step of providing the patient with an agent that reduces or eliminates Ruminococcaceae genus bacteria selected from an amino acid mixture, an antibacterial agent, a bacteriophage, or an antimicrobial CRISP-Cas system agent.

### Claim 19 (depends on 14)

The method of claim 14, wherein the human patient has brain injury that is chronic, mild, or undiagnosed, or is caused by stroke, hemorrhage, surgery, or radiation.

### Claim 20 (depends on 14)

The method of claim 14, wherein the composition is provided to the patient that further comprises an amino acid mixture that promotes a growth of Prevotella spp. or Bacteroidies spp., and an amino acid mixture that reduces or eliminates Ruminococcaceae genus bacteria.

### Claim 21

A method of treating brain injury associated fatigue or altered cognition (BIAFAC) in a human patient comprising:
identifying a human patient in need of treatment for a brain injury associated fatigue or altered cognition associated with an altered intestinal flora; and
providing the human patient with a composition comprising at least one of: a Prevotella spp or a Bacteroidies spp bacteria, or one or more agents that increase an amount of the Prevotella spp or the Bacteroidies spp bacteria in an intestinal flora of the human patient to reduce or eliminate the brain injury associated fatigue or altered cognition.

### Claim 22

A blood test assay that determines a biological profile associated with a bacterial flora that exacerbates a brain injury associated fatigue or altered cognition for testing a fecal sample from a patient that compares the biological profile from the patient to a database of a normal biological profile, wherein the bacterial flora detected is selected from Prevotella spp, Bacteroidies sp, or Ruminococcaceae genus bacteria.

### Claim 23

A kit for screening a patient for a brain injury associated fatigue or altered cognition of a patient and choosing a proper treatment based on the screening, the kit comprising:
a screening tool that screens the patient for a risk of brain injury associated fatigue or altered cognition, the screening tool comprising a questionnaire and further comprising a screening score system that determines the risk of the patient based on a cumulative point total from answers to the questionnaire;
a diagnostic test that categorizes the brain injury associated fatigue or altered cognition based on the cumulative point total from the questionnaire;
a fecal sample collection container for determining a bacterial flora in a fecal sample of the patient;
instructions for implementing the brain injury associated fatigue or altered cognition treatment; and
a brain injury associated fatigue or altered cognition treatment composition comprising one or more probiotic bacteria selected from at least one of: Prevotella spp or Bacteroidies spp, or one or more agents that increase the amount of Prevotella spp or Bacteroidies spp in an intestinal flora of the patient, wherein the composition comprises an amount effective to reduce or eliminate the brain injury associated fatigue or altered cognition.

### Claim 24

A method of diagnosing and treating a patient for brain injury associated fatigue or altered cognition, the method comprising:
using an algorithm implemented in a computer program to: screen a patient for a brain injury associated fatigue or altered cognition risk by scoring a questionnaire based on answers from the patient to the questionnaire, the scoring providing a cumulative point total, and determining the brain injury associated fatigue or altered cognition of the patient based on the cumulative point total from the questionnaire; and
choosing a proper brain injury associated fatigue or altered cognition treatment product if the brain injury associated fatigue or altered cognition risk exceeds a threshold, the brain injury associated fatigue or altered cognition treatment product comprising a composition comprising one or more probiotic bacteria selected from at least one of: Prevotella spp or Bacteroidies spp, or one or more agents that increase the amount of Prevotella spp or Bacteroidies spp in an intestinal flora of the patient, wherein the composition comprises an amount effective to reduce or eliminate the brain injury associated fatigue or altered cognition.
